Severe Asthma Market to Progress Upto USD 7 Billion by 2032 | DelveInsight

08 Jun 2022
www.prnewswire.com
Antibody
The increase in the Severe Asthma market size is a direct consequence of the expected launch of potential therapies an increase in the diagnosed prevalent population of Severe Asthma and increasing demand for personalized therapies.
LAS VEGAS, June 8, 2022 /PRNewswire/ -- DelveInsight's
Severe Asthma Market Insights report proffers a detailed comprehension of Severe Asthma market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Severe Asthma market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Some of the salient features from the
Severe Asthma Market Report
:
As per DelveInsight's analysis, the Severe Asthma market size in the 7MM was valued at almost
USD 6 Billion in 2021 and is anticipated to grow at a
CAGR of 5% for the study period (2019-2032).
Key Severe Asthma companies such as
Theravance Biopharma, and others are reported to bring a significant shift in the Severe Asthma market.
The Severe Asthma emerging therapies that are expected to launch in the forecast period include
GSK3511294, PT010, PT027, CSJ117, MRx-4DP0004, RG6173, CBP-201, PRS-060/AZD1402, BSI-045B, AVTX-002, and others.
As per DelveInsight, the United States has the highest percentage of Severe Asthma patients pool among the 7MM. In addition to that, according to DelveInsight's analysts among the EU5 countries, the United Kingdom has the largest patient population of Severe Asthma, whereas Spain had the lowest patient population of Severe Asthma.
Assessments as per DelveInsight's analysts indicate that Asthma diagnosed prevalence was more in adults than in pediatrics in the 7MM.
The development of well-designed, randomized, controlled non-crossover trials with the potential benefits for Severe Asthma patients will drive the market growth in the forecast period. Also, approval and entry of new drugs will change the Severe Asthma market dynamics in the future.
For further information on market impact by therapies, download the Severe Asthma market sample @
Severe Asthma Therapeutics Market Scenario
Asthma is the most common chronic respiratory disease all over the globe. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. It is a complex activity between airway inflammation and airway remodelling that results in airway hyper-responsiveness (AHR), which further leads to variable and excessive airway contraction. The characteristic Asthma symptoms include wheezing, shortness  of breath, cough, a sensation of tightness in the chest, straining of neck and chest muscles, rapid breathing, and changes in heart rate.
Asthma classification can be broadly done into intermittent or persistent. Here, Persistent asthma is further sub-divided based on severity into mild, moderate, and severe. Severe Asthma occurs due to various genetic, environmental, and psychological factors as well as respiratory infections. Severe AsthmaAsthma symptoms appear often in the nighttime with a persistent airflow obstruction with a forced expiratory volume (FEV1) of less than 60% predicted before treatment.
Severe Asthma Epidemiology Segmentation
As per the assessment of DelveInsight, the total diagnosed prevalent (adult + pediatric) cases of Asthma in the
7MM was observed to be approximately
54 million cases in
2021. These cases are expected to increase by 2032.
As per DelveInsight's estimates, among
7MM, the
United States had the highest diagnosed cases of adult Asthma with almost
20 million cases in
2021.
The
Severe Asthma Market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into
Total Diagnosed Prevalent (adult + pediatric) Cases of Asthma
Severity-specific Diagnosed Prevalent Cases of Asthma
Type-specific Diagnosed Prevalent Cases of Severe Asthma
Learn more about the Severe Asthma Population Trends for the 7 MM by downloading @
Severe Asthma Epidemiology Forecast Report
Severe Asthma Market Outlook
The fundamental goal of Asthma therapy is to minimize airway inflammation and also reduce the Asthma symptoms that come with it. To limit the likelihood of exacerbation, guidelines-based care focuses on illness severity and selecting the right medicinal therapy.
Inhaled corticosteroids are the most common chronic asthma treatment, but
quick-relief (reliever) or
rescue medications are frequently used to reduce acute Asthma symptoms.
Short-acting beta-agonists (SABAs) relieve airway bronchoconstriction quickly and are indicated as a symptom-relieving rescue drug. If asthma still isn't under control,
long-acting beta 2 agonists (LABA), montelukast, or
theophylline are added. If Asthma symptoms and flare-ups persist,
oral corticosteroids are prescribed.
There are currently six US FDA approved monoclonal antibodies for add-on biological Severe Asthma treatment. They include
Xolair (omalizumab) Novartis/Genentech.
Several new severe asthma therapeutic options are currently being developed. The key assets include
PT027 (BDA MDI/Budesonide/albuterol sulfate metered-dose inhaler) by
Bond Avillion. They are in the late stage of development and are expected to launch in the forecasted period (2022-2032). Several other companies are also developing drugs for Severe Asthma treatment including
Novartis (CSJ117), 4D pharma (MRx-4DP0004), Roche (RG6173), Pieris Pharma, and
AstraZeneca (PRS-060/AZD1402), Biosion (BSI-045B), among others.
Discover more about therapy set to grab substantial Severe Asthma market share @
Severe Asthma Market Landscape
Pipeline Therapies and Key Companies
PT027:
Avillion
MRx-4DP0004: 4D pharma
PRS-060/AZD1402: Pieris Pharma and
BSI-045B: Biosion
To know about more pipeline therapies covered in the report, visit @
Severe Asthma Pipeline Analysis, Clinical Trials, and Emerging Therapies
Severe Asthma market growth in the coming years is dependent on several factors such as  an increase in the diagnosed prevalent population of Severe Asthma and increasing demand for personalized therapies. Also, the development of well-designed, randomized, controlled non-crossover trials with the potential benefits for patients will drive the Severe Asthma market growth in the forecast period. In addition to that, approvals and entry of new drugs will change the Severe Asthma market dynamics in the future. Several pharmaceutical giants are investigating drugs for Severe Asthma treatment with an improved diagnostic approach leading to a rise in the Severe Asthma market in the coming years.
On the other hand, a lack of effective specific treatments in non-eosinophilic asthma (NEA) can represent an orphan asthma endotype serving as a drawback in the Severe Asthma market growth. Other factors such as a high cost of treatment, limitations in diagnosis, incorrect inhaler techniques, and poor adherence to treatment can all be considered as potential barriers to the rise of the Severe Asthma market.
Know which therapy is expected to score the touchdown first @
Severe Asthma Market Landscape and Forecast
Scope of the
Severe Asthma Market Report
Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key
Severe Asthma Pipeline Therapies: GSK3511294, PT010, PT027, CSJ117, MRx-4DP0004, RG6173, PRS-060/AZD1402, BSI-045B, AVTX-002, and others
Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and emerging therapies
Severe Asthma Market Dynamics:  Severe Asthma market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Severe Asthma Market Access and Reimbursement
Request for a Webex demo of the report
@
Severe Asthma Therapeutics Market
Table of Contents
Get in touch with our Business executive  @
Severe Asthma Market Landscape Analysis
Related Reports
DelveInsight's
"Asthma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Asthma, historical and forecasted epidemiology, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Allergic Asthma due to Dermatophagoides Farinae Market
DelveInsight's
"Allergic Asthma due to Dermatophagoides Farinae- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Allergic Asthma due to Dermatophagoides Farinae, historical and forecasted epidemiology, current Allergic Asthma due to Dermatophagoides Farinae treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
DelveInsight's
"Eosinophilic Asthma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Eosinophilic Asthma, historical and forecasted epidemiology, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Asthma Epidemiology
DelveInsight's
'Asthma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Asthma epidemiology in the 7MM, i.e., the United States, EU5  (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Pulse Oximeters Market
DelveInsight's
'Pulse Oximeters Market Insights, Competitive Landscape and Market Forecast - 2027' report deliver an in-depth understanding of Pulse Oximeters, historical and forecasted Pulse Oximeters market trends, market drivers, market barriers, and key companies involved like
Medtronic, Nonin Medical Inc, Lepu Medical Technology, TytoCare Ltd, VYAIRE, OMRON Corporation. Meditech Equipment Co ., Ltd, and several others.
Cough Assist Devices Market
"DelveInsight's
'Cough Assist Devices Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Cough Assist Devices and the historical and forecasted Cough Assist Devices market trends, market drivers & barriers, unmet needs and key companies involved such as
DelveInsight's
'Cough in Idiopathic Pulmonary Fibrosis (IPF)-Market Insights, Epidemiology and Market Forecast– 2032' report delivers an in-depth understanding of the cough in IPF, historical and forecasted epidemiology as well as the Cough in IPF market trends, market drivers & barriers, unmet needs and key companies involved such as
DelveInsight's
'Chronic Obstructive Pulmonary Disease (COPD)-Market Insights, Epidemiology, and Market Forecast–2032' report deliver an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) market trends, market drivers & barriers, unmet needs and key companies involved such as
AsthmaAsthma Diagnostic Devices Market
"DelveInsight's
'Asthma Diagnostic Devices Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Asthma Diagnostic Devices and the historical and forecasted Asthma Diagnostic Devices market trends, drivers, barriers, and key companies involved such as
Chronic Obstructive Pulmonary Disease Treatment Devices Market
"DelveInsight's
'Chronic Obstructive Pulmonary Disease Treatment Devices Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Chronic Obstructive Pulmonary Disease Treatment Devices and the historical and forecasted Chronic Obstructive Pulmonary Disease Treatment Devices market trends, drivers, barriers and key companies involved such as
Interested to know more about the breakthrough happenings? Take a look at the posts below
Asthma: Rising Prevalence And The Key Challenges In The Management
Chronic Refractory Cough Market
and the Monopoly of the Over-The-Counter Drugs
and Their Prolonged Impact on the Quality of Life
About
DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect With Us at LinkedIn
| Facebook | Twitter
Contact Us
[email protected]
+1(919)321-6187
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.